Table 3 CD4⁺CD25⁺FoxP3⁺ Tregs in EAE treatment

From: Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy

EAE	N^o of Tregs	Administration^a	Modification	Propagation	Phenotype	Effect on EAE	Ref
PLP_178–191 SJL/J MBP_87–99 SJL/J MOG_35–55 (SJL/J x C57BL/6) F1	1 × 10⁶	Prophylactic i.v. 1 d.b.i.	5B6 Tregs	PLP 30 µg/ml	CTLA4⁺ IL-10	Amelioration	¹⁰⁷
PLP_139–151 SJL/J	1 × 10⁵	Prophylactic i.v. 2 d.b.i.	No	No	LAP+, CTLA4+, GITR+, ICOS+, PD1+, OX40+, CD103+, Tim3+ TGF-β	Amelioration	¹⁰⁹
MBP Ac1-9 C57BL/6	1 × 10⁵	Prophylactic i.p. 0 d.p.i.	CRP-MBP mice	No	n.a.	Prevention	¹¹⁰
MBP Ac1-9 B10.PL PLP_139–151 (B10.PL x SJL) F1	1 × 10⁵ 3 × 10⁵ 4–5 × 10⁵ 1 × 10⁶	Prophylactic i.v. 0 d.p.i. Late-therapeutic i.v. 18 d.p.i	Tg4	No	CD62L^high	Prevention Amelioration	¹⁰²
PLP_139-151 SJL/J	2 × 10⁵	Prophylactic i.v. 0 d.b.i.	GFP-Foxp3 x 5B6 TCR Tg	PLP_139–151 (5 µM), TGF-β, RA, IL-2	CD62L^inter CD103^high CD73⁺ CTLA4⁺ GITR⁺	Prevention	¹⁰⁸
C57BL/6 MOG_35–55	1 × 10⁵	Late-therapeutic i.n. 15 d.p.i.	CAR-MOG	IL-2	n.a.	Prevention	¹⁰³
C57BL/6 MOG^35–55	1 × 10⁶	Therapeutic i.p. 10 d.p.i.	NO-Tregs	No	IL-10	Amelioration	¹⁰⁴
MBP Ac1-9 Tg4	5 × 10⁶	Prophylactic i.p. 2–3 d.b.i.	Tg4	IL-2, TGF-β1	Helios⁻Eos⁻CD103⁺ GITR⁺NRP-1⁺ CD62L⁺ CTLA4 + IL-10	Prevention	¹⁰⁶
MBP Ac1-9 (C57BL/6 × B10.PL)F1	1 × 10⁶	Prophylactic i.v. 1 d.b.i.	Tg4 Tbet^-	No	CD62L^hi	Prevention	¹¹¹
MOG_35–55 (Tg(HLA-DR15)#Lfug)	2 × 10⁶	Late-prohylactic i.v. 7 d.p.i	Ob2F3	MBP_85–99, IL-2	Helios, GARP, and LAP	Amelioration	¹¹²
MOG_35–55 or PLP_178–191 C57BL/6	1 × 10⁶	Prophylactic i.v. 1 d.b.i. Therapeutic i.v. 9 d.p.i	MOG/NF-M TCR	IL-2, rapamycin	n.a.	Amelioration	¹⁰⁵

ATRA all-trans retinoic acid, CAR chimeric antigen receptor, CRP C-reactive protein, d.b.i. days before immunization, d.p.i. days post immunization, inh. inhibition, n.a. not analyzed, NF-M neurofilament-medium, o.e. over-expression
^aProphylactic treatment: treatment before or at the moment of EAE induction; late-prophylactic treatment: treatment after EAE induction but prior to clinical onset and therapeutic treatment: first dose administrated to mice with the first clinical signs and late-therapeutic: treatment 5–8 days after the initial clinical signs

Back to article page

Table 3 CD4⁺CD25⁺FoxP3⁺ Tregs in EAE treatment

Search

Quick links